GH Research PLC (GHRS)
Automate Your Wheel Strategy on GHRS
With Tiblio's Option Bot, you can configure your own wheel strategy including GHRS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GHRS
- Rev/Share 0.0
- Book/Share 5.3459
- PB 2.3588
- Debt/Equity 0.0021
- CurrentRatio 29.7104
- ROIC -0.1657
- MktCap 782174341.0
- FreeCF/Share -0.7118
- PFCF -18.9375
- PE -17.378
- Debt/Assets 0.0021
- DivYield 0
- ROE -0.192
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | GHRS | Cantor Fitzgerald | -- | Overweight | -- | $25 | June 4, 2025 |
| Initiation | GHRS | Guggenheim | -- | Buy | -- | $32 | March 13, 2025 |
| Initiation | GHRS | RBC Capital Mkts | -- | Outperform | -- | $31 | March 7, 2025 |
| Initiation | GHRS | Cantor Fitzgerald | -- | Overweight | -- | $14 | Feb. 13, 2025 |
News
GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
DUBLIN, May 08, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the quarter ended March 31, 2025, and provided updates on its business.
Read More
What Makes GH Research (GHRS) a New Buy Stock
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive
GH Research (GHRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
GH Research Reports Full Year 2024 Financial Results and Provides Business Updates
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025 Phase 1 clinical trial to evaluate proprietary aerosol delivery device in healthy volunteers is ongoing in the UK Full response to the IND hold on track for submission in mid-2025 Cash, cash equivalents, other financial assets and marketable securities of $182.6 million as of December 31, 2024 Net cash proceeds of an additional $139.8 million from public offering received in February 2025 DUBLIN, Feb. 27, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), …
Read More
About GH Research PLC (GHRS)
- IPO Date 2021-06-25
- Website https://www.ghres.com
- Industry Biotechnology
- CEO Dr. Velichka Valcheva M.D., M.Sc.
- Employees 50